ArQule has designed the MOSAIC clinical trial to determine whether drug candidate miransertib can effectively treat individuals with Proteus syndrome and PIK3CA-related overgrowth spectrum syndromes. Due to miransertib’s inhibition of AKT activity, eligible participants must have Proteus syndrome or a PIK3CA-related overgrowth spectrum syndromes (PROS) with a documented mutation in either the AKT1 or PIK3CA gene.
For additional study details, please visit our clinicaltrials.gov page (NCT03094832).
For more detailed information about Proteus syndrome and PROS, we encourage you to take a look at the below resources:
Contact firstname.lastname@example.org for more information about the trial.